Improvement in patient‐reported “taste” and association with smell in dupilumab‐treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS‐24 and SINUS‐52 trials

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predomi nantly type 2- mediated inflammatory disease of the nasal cavity and paranasal sinuses. 1 Persistent symptoms of severe CRSwNP include nasal blockage and nasal discharge and olfactory dysfunc tion, with patients frequently reporting altered sense of smell and taste. In a large, retrospective study of patients with CRSwNP re quiring sinus surgery ( n = 1784), nasal blockage and altered sense of smell and taste (measured using the 22- item Sino- Nasal Outcome Test [SNOT- 22]) were the most prevalent (≥90% of patients) and se vere symptoms. 2 These common symptoms are highly burdensome for patients, severely impacting their health- related quality of life (HRQoL). 1,3 Therapeutic options for patients with CRSwNP are limited, and principally include topical corticosteroids, sinonasal surgery and systemic corticosteroids (SCS). However, such treatments may confer a further increase in disease burden due to short- and long- term adverse events associated with SCS, 4 and a high rate of recurrence post- sinus surgery. 5 Biologic agents targeting the un derlying immune- related pathophysiology of CRSwNP are emerg ing as an effective treatment for CRSwNP. Dupilumab is a fully human VelocImmune ® - derived monoclonal antibody that binds to interleukin (IL)- 4R α to inhibit signalling of both IL- 4 and IL- 13, which are key and central drivers of type 2